Complete cytogenetic and molecular responses to interferon-?-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis-Reference-Cited by-同舟云学术

Complete cytogenetic and molecular responses to interferon-?-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis

Published:2003-02-03 Issue:4 Volume:97 Page:1033-1041
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Kantarjian Hagop M.,O'Brien Susan,Cortes Jorge E.,Shan Jianqin,Giles Francis J.,Rios Mary Beth,Faderl Stefan H.,Wierda William G.,Ferrajoli Alessandra,Verstovsek Srdan,Keating Michael J.,Freireich Emil J.,Talpaz Moshe

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference30 articles.

1. Hematologic Remission and Cytogenetic Improvement Induced by Recombinant Human Interferon AlphaAin Chronic Myelogenous Leukemia

2. Clinical investigation of human alpha interferon in chronic myelogenous leukemia

3. Chronic myelogenous leukemia: a concise update

4. Prolonged Survival in Chronic Myelogenous Leukemia after Cytogenetic Response to Interferon-α Therapy

5. UK Medical Research Council randomised, multicentre trial of interferon-αn1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response

Cited by 196 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chronic myeloid leukaemia: Biology and therapy;Blood Reviews;2024-05

2. 25 years of experience in the treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: results, opportunities, questions;Meditsinskiy sovet = Medical Council;2024-01-17

3. What is the impact of failing to achieve TKI therapy milestones in chronic myeloid leukemia;Leukemia;2023-10-05

4. Exploiting the potential of the ubiquitin-proteasome system in overcoming tyrosine kinase inhibitor resistance in chronic myeloid leukemia;Genes & Diseases;2023-10

5. Revisiting six established practices in the treatment of chronic myeloid leukaemia;The Lancet Haematology;2023-10